Research Site

Chisinau MD-2025

2 studies enrolling now · 12 studies all time

What they study most

Advanced or Metastatic Non-small Cell Lung Cancer, Biliary Tract Cancer, Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer, Locally Advanced or Metastatic Urothelial Cell Carcinoma, Multiple Sclerosis, Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders, Non-Small-Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Relapsing-Remitting Multiple Sclerosis, Systemic Lupus Erythematosus

Studies at this site

• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 — Recruiting now
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC — Running, not enrolling
• A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer — Running, not enrolling
• N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• Phase IIb Study of IFN-K in Systemic Lupus Erythematosus — Stopped early
• A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma — Stopped early
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 — Stopped early
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed